KATHRYN GRAMLICH: Open Payments
NPI 1710309588 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,088 in 68 payments from 18 companies in 2025. Trend: 2023 $2,689 · 2024 $2,168 · 2025 $1,088
Food & beverage: $1,088
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $237 |
| Novo Nordisk Inc | 18 | $200 |
| GlaxoSmithKline, LLC. | 6 | $117 |
| Novartis Pharmaceuticals Corporation | 4 | $85 |
| Verona Pharma, Inc. | 4 | $79 |
| PFIZER INC. | 3 | $64 |
| Exact Sciences Corporation | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| JAZZ PHARMACEUTICALS INC. | 1 | $39 |
| Esperion Therapeutics, Inc. | 2 | $32 |
Products named: VRAYLAR, TRELEGY ELLIPTA, Ozempic, Ohtuvayre, LEQVIO, QULIPTA, ELIQUIS, Wegovy.
Industry payments across IN — which companies pay providers there.
